Mirum Pharmaceuticals: Specialist in Rare Liver Diseases with $4 Billion Potential!

Mirum Pharmaceuticals is transforming from its main product LIVMARLI into a diversified specialty pharmaceutical company for rare genetic diseases. The pipeline offers a revenue potential of over $4 billion. Phase 2 data for Zilurgisertib, along with primary endpoints for Volixibat and Brelovitug, underpin long-term expansion plans. The first quarter showed impressive growth with a revenue increase of over 43%. The annual forecast has been raised to between $660 million and $680 million, an increase of up to 30%.   Mirum Pharmaceuticals...